Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences

So-Hyeon Hong, Kyung Mook Choi, So-Hyeon Hong, Kyung Mook Choi

Abstract

The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease.

Keywords: cardiometabolic disease; insulin resistance; sarcopenic obesity.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. United Nations . World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. United Nations; New York, NY, USA: 2017.
    1. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyere O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Writing Group for the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169.
    1. Roubenoff R. Sarcopenic obesity: The confluence of two epidemics. Obes. Res. 2004;12:887–888. doi: 10.1038/oby.2004.107.
    1. Kim Y., White T., Wijndaele K., Sharp S.J., Wareham N.J., Brage S. Adiposity and grip strength as long-term predictors of objectively measured physical activity in 93,015 adults: The UK Biobank study. Int. J. Obes. 2017;41:1361. doi: 10.1038/ijo.2017.122.
    1. Ma J., Hwang S.J., McMahon G.M., Curhan G.C., Mclean R.R., Murabito J.M., Fox C.S. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity. Obesity. 2016;24:526–534. doi: 10.1002/oby.21356.
    1. Scott D., Chandrasekara S.D., Laslett L.L., Cicuttini F., Ebeling P.R., Jones G. Associations of sarcopenic obesity and dynapenic obesity with bone mineral density and incident fractures over 5–10 years in community-dwelling older adults. Calcif. Tissue Int. 2016;99:30–42. doi: 10.1007/s00223-016-0123-9.
    1. Zhang X., Xie X., Dou Q., Liu C., Zhang W., Yang Y., Deng R., Cheng A.S. Association of sarcopenic obesity with the risk of all-cause mortality among adults over a broad range of different settings: A updated meta-analysis. BMC Geriatr. 2019;19:183. doi: 10.1186/s12877-019-1195-y.
    1. Benziger C.P., Roth G.A., Moran A.E. The global burden of disease study and the preventable burden of NCD. Glob. Heart. 2016;11:393–397. doi: 10.1016/j.gheart.2016.10.024.
    1. Samuel V.T., Shulman G.I. The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. J. Clin. Investig. 2016;126:12–22. doi: 10.1172/JCI77812.
    1. Abdul-Ghani M.A., DeFronzo R.A. Pathogenesis of insulin resistance in skeletal muscle. J. Biomed. Biotechnol. 2010;2010:476279. doi: 10.1155/2010/476279.
    1. Kalyani R.R., Corriere M., Ferrucci L. Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2:819–829. doi: 10.1016/S2213-8587(14)70034-8.
    1. Yamashita M., Kamiya K., Matsunaga A., Kitamura T., Hamazaki N., Matsuzawa R., Nozaki K., Tanaka S., Nakamura T., Maekawa E., et al. Prognostic value of sarcopenic obesity estimated by computed tomography in patients with cardiovascular disease and undergoing surgery. J. Cardiol. 2019;74:273–278. doi: 10.1016/j.jjcc.2019.02.010.
    1. Batsis J.A., Villareal D.T. Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies. Nat. Rev. Endocrinol. 2018;14:513–537. doi: 10.1038/s41574-018-0062-9.
    1. Rolland Y., Lauwers-Cances V., Cristini C., Abellan van Kan G., Janssen I., Morley J.E., Vellas B. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l’OSteoporose) Study. Am. J. Clin. Nutr. 2009;89:1895–1900. doi: 10.3945/ajcn.2008.26950.
    1. Kim T.N., Park M.S., Lee E.J., Chung H.S., Yoo H.J., Kang H.J., Song W., Baik S.H., Choi K.M. Comparisons of three different methods for defining sarcopenia: An aspect of cardiometabolic risk. Sci. Rep. 2017;7:6491. doi: 10.1038/s41598-017-06831-7.
    1. Baumgartner R.N. Body composition in healthy aging. Ann. N. Y. Acad. Sci. 2000;904:437–448. doi: 10.1111/j.1749-6632.2000.tb06498.x.
    1. Davison K.K., Ford E.S., Cogswell M.E., Dietz W.H. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J. Am. Geriatr. Soc. 2002;50:1802–1809. doi: 10.1046/j.1532-5415.2002.50508.x.
    1. Studenski S.A., Peters K.W., Alley D.E., Cawthon P.M., McLean R.R., Harris T.B., Ferrucci L., Guralnik J.M., Fragala M.S., Kenny A.M., et al. The FNIH sarcopenia project: Rationale, study description, conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med. Sci. 2014;69:547–558. doi: 10.1093/gerona/glu010.
    1. Chen L.K., Liu L.K., Woo J., Assantachai P., Auyeung T.W., Bahyah K.S., Chou M.Y., Chen L.Y., Hsu P.S., Krairit O., et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. J. Am. Med. Dir. Assoc. 2014;15:95–101. doi: 10.1016/j.jamda.2013.11.025.
    1. Kim T.N., Yang S.J., Yoo H.J., Lim K.I., Kang H.J., Song W., Seo J.A., Kim S.G., Kim N.H., Baik S.H., et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: The Korean sarcopenic obesity study. Int. J. Obes. 2009;33:885–892. doi: 10.1038/ijo.2009.130.
    1. Malmstrom T.K., Miller D.K., Simonsick E.M., Ferrucci L., Morley J.E. SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J. Cachexia Sarcopenia Muscle. 2016;7:28–36. doi: 10.1002/jcsm.12048.
    1. Nilwik R., Snijders T., Leenders M., Groen B.B.L., van Kranenburg J., Verdijk L.B., van Loon L.J.C. The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size. Exp. Gerontol. 2013;48:492–498. doi: 10.1016/j.exger.2013.02.012.
    1. Gannon J., Doran P., Kirwan A., Ohlendieck K. Drastic increase of myosin light chain MLC-2 in senescent skeletal muscle indicates fast-to-slow fibre transition in sarcopenia of old age. Eur. J. Cell Biol. 2009;88:685–700. doi: 10.1016/j.ejcb.2009.06.004.
    1. Delbono O. Neural control of aging skeletal muscle. Aging Cell. 2003;2:21–29. doi: 10.1046/j.1474-9728.2003.00011.x.
    1. Gemmink A., Goodpaster B.H., Schrauwen P., Hesselink M.K.C. Intramyocellular lipid droplets and insulin sensitivity, the human perspective. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2017;1862:1242–1249. doi: 10.1016/j.bbalip.2017.07.010.
    1. Brøns C., Grunnet L.G. Mechanisms in endocrinology: Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes: A causal mechanism or an innocent bystander? Eur. J. Endocrinol. 2017;176:R67–R78. doi: 10.1530/EJE-16-0488.
    1. Pol A., Gross S.P., Parton R.G. Review: Biogenesis of the multifunctional lipid droplet: Lipids, proteins, and sites. J. Cell Biol. 2014;204:635–646. doi: 10.1083/jcb.201311051.
    1. Shulman G.I. Cellular mechanisms of insulin resistance. J. Clin. Investig. 2000;106:171–176. doi: 10.1172/JCI10583.
    1. Affourtit C. Mitochondrial involvement in skeletal muscle insulin resistance: A case of imbalanced bioenergetics. Biochim. Biophys. Acta. 2016;1857:1678–1693. doi: 10.1016/j.bbabio.2016.07.008.
    1. Rivas D.A., McDonald D.J., Rice N.P., Haran P.H., Dolnikowski G.G., Fielding R.A. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016;310:R561–R569. doi: 10.1152/ajpregu.00198.2015.
    1. Zhu S., Tian Z., Torigoe D., Zhao J., Xie P., Sugizaki T., Sato M., Horiguchi H., Terada K., Kadomatsu T. Aging-and obesity-related peri-muscular adipose tissue accelerates muscle atrophy. PLoS ONE. 2019;14:e0221366. doi: 10.1371/journal.pone.0221366.
    1. Peters S.J., Samjoo I.A., Devries M.C., Stevic I., Robertshaw H.A., Tarnopolsky M.A. Perilipin family (PLIN) proteins in human skeletal muscle: The effect of sex, obesity, and endurance training. Appl. Physiol. Nutr. Metab. 2012;37:724–735. doi: 10.1139/h2012-059.
    1. Bosma M., Sparks L.M., Hooiveld G.J., Jorgensen J.A., Houten S.M., Schrauwen P., Kersten S., Hesselink M.K. Overexpression of PLIN5 in skeletal muscle promotes oxidative gene expression and intramyocellular lipid content without compromising insulin sensitivity. Biochim. Biophys. Acta. 2013;1831:844–852. doi: 10.1016/j.bbalip.2013.01.007.
    1. Harris L.A., Skinner J.R., Shew T.M., Pietka T.A., Abumrad N.A., Wolins N.E. Perilipin 5-Driven Lipid Droplet Accumulation in Skeletal Muscle Stimulates the Expression of Fibroblast Growth Factor 21. Diabetes. 2015;64:2757–2768. doi: 10.2337/db14-1035.
    1. Conte M., Vasuri F., Bertaggia E., Armani A., Santoro A., Bellavista E., Degiovanni A., D’Errico-Grigioni A., Trisolino G., Capri M., et al. Differential expression of perilipin 2 and 5 in human skeletal muscle during aging and their association with atrophy-related genes. Biogerontology. 2015;16:329–340. doi: 10.1007/s10522-014-9549-5.
    1. Bosma M. Lipid droplet dynamics in skeletal muscle. Exp. Cell Res. 2016;340:180–186. doi: 10.1016/j.yexcr.2015.10.023.
    1. Cho K.A., Kang P.B. PLIN2 inhibits insulin-induced glucose uptake in myoblasts through the activation of the NLRP3 inflammasome. Int. J. Mol. Med. 2015;36:839–844. doi: 10.3892/ijmm.2015.2276.
    1. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 2003;112:1796–1808. doi: 10.1172/JCI200319246.
    1. Morris D.L., Cho K.W., DelProposto J.L., Oatmen K.E., Geletka L.M., Martinez-Santibanez G., Singer K., Lumeng C.N. Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice. Diabetes. 2013;62:2762–2772. doi: 10.2337/db12-1404.
    1. Bing C. Is interleukin-1β a culprit in macrophage-adipocyte crosstalk in obesity? Adipocyte. 2015;4:149–152. doi: 10.4161/21623945.2014.979661.
    1. Castoldi A., Naffah de Souza C., Câmara N.O.S., Moraes-Vieira P.M. The macrophage switch in obesity development. Front. Immunol. 2016;6:637. doi: 10.3389/fimmu.2015.00637.
    1. Kob R., Bollheimer L.C., Bertsch T., Fellner C., Djukic M., Sieber C.C., Fischer B.E. Sarcopenic obesity: Molecular clues to a better understanding of its pathogenesis? Biogerontology. 2015;16:15–29. doi: 10.1007/s10522-014-9539-7.
    1. Kratz M., Coats B.R., Hisert K.B., Hagman D., Mutskov V., Peris E., Schoenfelt K.Q., Kuzma J.N., Larson I., Billing P.S. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 2014;20:614–625. doi: 10.1016/j.cmet.2014.08.010.
    1. Fitzgibbons T.P., Czech M.P. Emerging evidence for beneficial macrophage functions in atherosclerosis and obesity-induced insulin resistance. J. Mol. Med. 2016;94:267–275. doi: 10.1007/s00109-016-1385-4.
    1. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br. J. Pharmacol. 2008;154:522–528. doi: 10.1038/bjp.2008.118.
    1. Nettleship J., Pugh P., Channer K., Jones T., Jones R. Inverse relationship between serum levels of interleukin-1β and testosterone in men with stable coronary artery disease. Horm. Metab. Res. 2007;39:366–371. doi: 10.1055/s-2007-976543.
    1. Mudali S., Dobs A.S. Effects of testosterone on body composition of the aging male. Mech. Ageing Dev. 2004;125:297–304. doi: 10.1016/j.mad.2004.01.004.
    1. Abdulnour J., Doucet E., Brochu M., Lavoie J.M., Strychar I., Rabasa-Lhoret R., Prud’homme D. The effect of the menopausal transition on body composition and cardiometabolic risk factors: A Montreal-Ottawa New Emerging Team group study. Menopause. 2012;19:760–767. doi: 10.1097/gme.0b013e318240f6f3.
    1. Egerman M.A., Glass D.J. Signaling pathways controlling skeletal muscle mass. Crit. Rev. Biochem. Mol. Biol. 2014;49:59–68. doi: 10.3109/10409238.2013.857291.
    1. O’Neill B.T., Lauritzen H.P., Hirshman M.F., Smyth G., Goodyear L.J., Kahn C.R. Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep. 2015;11:1220–1235. doi: 10.1016/j.celrep.2015.04.037.
    1. Kelly D., Mitrakou A., Marsh H., Schwenk F., Benn J., Sonnenberg G., Archangeli M., Aoki T., Sorensen J., Berger M., et al. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J. Clin. Investig. 1988;81:1563–1571. doi: 10.1172/JCI113489.
    1. Groop L.C., Bonadonna R.C., DelPrato S., Ratheiser K., Zyck K., Ferrannini E., DeFronzo R.A. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J. Clin. Investig. 1989;84:205–213. doi: 10.1172/JCI114142.
    1. Kimball S.R., Horetsky R.L., Jefferson L.S. Signal transduction pathways involved in the regulation of protein synthesis by insulin in L6 myoblasts. Am. J. Physiol. Cell Physiol. 1998;274:C221–C228. doi: 10.1152/ajpcell.1998.274.1.C221.
    1. Guillet C., Prod’homme M., Balage M., Gachon P., Giraudet C., Morin L., Grizard J., Boirie Y. Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans. FASEB J. 2004;18:1586–1587. doi: 10.1096/fj.03-1341fje.
    1. Fujita S., Rasmussen B.B., Cadenas J.G., Drummond M.J., Glynn E.L., Sattler F.R., Volpi E. Aerobic exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/mammalian target of rapamycin signaling. Diabetes. 2007;56:1615–1622. doi: 10.2337/db06-1566.
    1. Boura-Halfon S., Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2009;296:E581–E591. doi: 10.1152/ajpendo.90437.2008.
    1. Hafizi Abu Bakar M., Kian Kai C., Wan Hassan W.N., Sarmidi M.R., Yaakob H., Zaman Huri H. Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: The roles of long chain fatty acids. Diabetes Metab. Res. Rev. 2015;31:453–475. doi: 10.1002/dmrr.2601.
    1. Stinkens R., Goossens G.H., Jocken J.W., Blaak E.E. Targeting fatty acid metabolism to improve glucose metabolism. Obes. Rev. 2015;16:715–757. doi: 10.1111/obr.12298.
    1. Kalinkovich A., Livshits G. Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res. Rev. 2017;35:200–221. doi: 10.1016/j.arr.2016.09.008.
    1. Patsouris D., Cao J.-J., Vial G., Bravard A., Lefai E., Durand A., Durand C., Chauvin M.-A., Laugerette F., Debard C. Insulin resistance is associated with MCP1-mediated macrophage accumulation in skeletal muscle in mice and humans. PLoS ONE. 2014;9:e110653. doi: 10.1371/journal.pone.0110653.
    1. Evers-van Gogh I.J., Oteng A.-B., Alex S., Hamers N., Catoire M., Stienstra R., Kalkhoven E., Kersten S. Muscle-specific inflammation induced by MCP-1 overexpression does not affect whole-body insulin sensitivity in mice. Diabetologia. 2016;59:624–633. doi: 10.1007/s00125-015-3822-2.
    1. Wu H., Ballantyne C.M. Skeletal muscle inflammation and insulin resistance in obesity. J. Clin. Investig. 2017;127:43–54. doi: 10.1172/JCI88880.
    1. Lackey D.E., Olefsky J.M. Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 2016;12:15. doi: 10.1038/nrendo.2015.189.
    1. Jové M., Planavila A., Sánchez R.M., Merlos M., Laguna J.C., Vázquez-Carrera M. Palmitate induces tumor necrosis factor-α expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-κB activation. Endocrinology. 2006;147:552–561. doi: 10.1210/en.2005-0440.
    1. Gao Z., Hwang D., Bataille F., Lefevre M., York D., Quon M.J., Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J. Biol. Chem. 2002;277:48115–48121. doi: 10.1074/jbc.M209459200.
    1. Henstridge D.C., Bruce C.R., Pang C.P., Lancaster G.I., Allen T.L., Estevez E., Gardner T., Weir J.M., Meikle P.J., Lam K.S.L., et al. Skeletal muscle-specific overproduction of constitutively activated c-Jun N-terminal kinase (JNK) induces insulin resistance in mice. Diabetologia. 2012;55:2769–2778. doi: 10.1007/s00125-012-2652-8.
    1. Li P., Oh D.Y., Bandyopadhyay G., Lagakos W.S., Talukdar S., Osborn O., Johnson A., Chung H., Maris M., Ofrecio J.M., et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat. Med. 2015;21:239–247. doi: 10.1038/nm.3800.
    1. Sabio G., Davis R.J. cJun NH2-terminal kinase 1 (JNK1): Roles in metabolic regulation of insulin resistance. Trends Biochem. Sci. 2010;35:490–496. doi: 10.1016/j.tibs.2010.04.004.
    1. Talbot N.A., Wheeler-Jones C.P., Cleasby M.E. Palmitoleic acid prevents palmitic acid-induced macrophage activation and consequent p38 MAPK-mediated skeletal muscle insulin resistance. Mol. Cell. Endocrinol. 2014;393:129–142. doi: 10.1016/j.mce.2014.06.010.
    1. Senn J.J. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J. Biol. Chem. 2010;285:14842. doi: 10.1074/jbc.A109.513304.
    1. Vijayvargia R., Mann K., Weiss H.R., Pownall H.J., Ruan H. JNK deficiency enhances fatty acid utilization and diverts glucose from oxidation to glycogen storage in cultured myotubes. Obesity. 2010;18:1701–1709. doi: 10.1038/oby.2009.501.
    1. Mashili F., Chibalin A.V., Krook A., Zierath J.R. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes. Diabetes. 2013;62:457–465. doi: 10.2337/db12-0337.
    1. White A.T., Schenk S. Knockout of STAT3 in skeletal muscle does not enhance insulin action. Diabetologia. 2013;56:S250.
    1. Tanti J.-F., Ceppo F., Jager J., Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front. Endocrinol. 2013;3:181. doi: 10.3389/fendo.2012.00181.
    1. Ueki K., Kondo T., Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 2004;24:5434–5446. doi: 10.1128/MCB.24.12.5434-5446.2004.
    1. Sachithanandan N., Graham K.L., Galic S., Honeyman J.E., Fynch S.L., Hewitt K.A., Steinberg G.R., Kay T.W. Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance. Diabetes. 2011;60:2023–2031. doi: 10.2337/db11-0259.
    1. Williams J.J.L., Alotaiq N., Mullen W., Burchmore R., Liu L., Baillie G.S., Schaper F., Pilch P.F., Palmer T.M. Interaction of suppressor of cytokine signalling 3 with cavin-1 links SOCS3 function and cavin-1 stability. Nat. Commun. 2018;9:168. doi: 10.1038/s41467-017-02585-y.
    1. Dempsey E.C., Newton A.C., Mochly-Rosen D., Fields A.P., Reyland M.E., Insel P.A., Messing R.O. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell Mol. Physiol. 2000;279:L429–L438. doi: 10.1152/ajplung.2000.279.3.L429.
    1. Mellor H., Parker P.J. The extended protein kinase C superfamily. Biochem. J. 1998;332:281–292. doi: 10.1042/bj3320281.
    1. Szendroedi J., Yoshimura T., Phielix E., Koliaki C., Marcucci M., Zhang D., Jelenik T., Müller J., Herder C., Nowotny P. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl. Acad. Sci. USA. 2014;111:9597–9602. doi: 10.1073/pnas.1409229111.
    1. Kim J.K., Fillmore J.J., Sunshine M.J., Albrecht B., Higashimori T., Kim D.-W., Liu Z.-X., Soos T.J., Cline G.W., O’Brien W.R. PKC-θ knockout mice are protected from fat-induced insulin resistance. J. Clin. Investig. 2004;114:823–827. doi: 10.1172/JCI200422230.
    1. Chung H.S., Choi K.M. Adipokines and myokines: A pivotal role in metabolic and cardiovascular disorders. Curr. Med. Chem. 2018;25:2401–2415. doi: 10.2174/0929867325666171205144627.
    1. Fischer C.P., Plomgaard P., Hansen A.K., Pilegaard H., Saltin B., Pedersen B.K. Endurance training reduces the contraction-induced interleukin-6 mRNA expression in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2004;287:E1189–E1194. doi: 10.1152/ajpendo.00206.2004.
    1. Wolsk E., Mygind H., Grondahl T.S., Pedersen B.K., van Hall G. IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2010;299:E832–E840. doi: 10.1152/ajpendo.00328.2010.
    1. Ellingsgaard H., Hauselmann I., Schuler B., Habib A.M., Baggio L.L., Meier D.T., Eppler E., Bouzakri K., Wueest S., Muller Y.D., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011;17:1481–1489. doi: 10.1038/nm.2513.
    1. Kraakman M.J., Kammoun H.L., Allen T.L., Deswaerte V., Henstridge D.C., Estevez E., Matthews V.B., Neill B., White D.A., Murphy A.J. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21:403–416. doi: 10.1016/j.cmet.2015.02.006.
    1. Langkilde A., Petersen J., Henriksen J.H., Jensen F.K., Gerstoft J., Eugen-Olsen J., Andersen O. Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls. Immun. Ageing. 2015;12:9. doi: 10.1186/s12979-015-0036-x.
    1. McKay B.R., Ogborn D.I., Baker J.M., Toth K.G., Tarnopolsky M.A., Parise G. Elevated SOCS3 and altered IL-6 signaling is associated with age-related human muscle stem cell dysfunction. Am. J. Physiol. Cell Physiol. 2013;304:C717–C728. doi: 10.1152/ajpcell.00305.2012.
    1. Ballak D.B., van Essen P., van Diepen J.A., Jansen H., Hijmans A., Matsuguchi T., Sparrer H., Tack C.J., Netea M.G., Joosten L.A., et al. MAP3K8 (TPL2/COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice. PLoS ONE. 2014;9:e89615. doi: 10.1371/journal.pone.0089615.
    1. Puz P., Lasek-Bal A. Repeated measurements of serum concentrations of TNF-alpha, interleukin-6 and interleukin-10 in the evaluation of internal carotid artery stenosis progression. Atherosclerosis. 2017;263:97–103. doi: 10.1016/j.atherosclerosis.2017.06.008.
    1. Forti L.N., Njemini R., Beyer I., Eelbode E., Meeusen R., Mets T., Bautmans I. Strength training reduces circulating interleukin-6 but not brain-derived neurotrophic factor in community-dwelling elderly individuals. Age. 2014;36:9704. doi: 10.1007/s11357-014-9704-6.
    1. Boström P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., Rasbach K.A., Boström E.A., Choi J.H., Long J.Z. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463. doi: 10.1038/nature10777.
    1. Zhang Y., Li R., Meng Y., Li S.W., Donelan W., Zhao Y., Qi L., Zhang M.X., Wang X.L., Cui T.X., et al. Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling. Diabetes. 2014;63:514–525. doi: 10.2337/db13-1106.
    1. Natalicchio A., Marrano N., Biondi G., Spagnuolo R., Labarbuta R., Porreca I., Cignarelli A., Bugliani M., Marchetti P., Perrini S. The myokine irisin is released in response to saturated fatty acids and promotes pancreatic β-cell survival and insulin secretion. Diabetes. 2017;66:2849–2856. doi: 10.2337/db17-0002.
    1. Zhou X., Li R., Liu X., Wang L., Hui P., Chan L., Saha P.K., Hu Z. ROCK1 reduces mitochondrial content and irisin production in muscle suppressing adipocyte browning and impairing insulin sensitivity. Sci. Rep. 2016;6:29669. doi: 10.1038/srep29669.
    1. Kurdiova T., Balaz M., Vician M., Maderova D., Vlcek M., Valkovic L., Srbecky M., Imrich R., Kyselovicova O., Belan V., et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: In vivo and in vitro studies. J. Physiol. 2014;592:1091–1107. doi: 10.1113/jphysiol.2013.264655.
    1. Tsuchiya Y., Ando D., Takamatsu K., Goto K. Resistance exercise induces a greater irisin response than endurance exercise. Metab. Clin. Exp. 2015;64:1042–1050. doi: 10.1016/j.metabol.2015.05.010.
    1. Norheim F., Langleite T.M., Hjorth M., Holen T., Kielland A., Stadheim H.K., Gulseth H.L., Birkeland K.I., Jensen J., Drevon C.A. The effects of acute and chronic exercise on PGC-1alpha, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 2014;281:739–749. doi: 10.1111/febs.12619.
    1. Choi K.M., Hwang S.Y., Han K., Chung H.S., Kim N.H., Yoo H.J., Seo J.-A., Kim S.G., Kim N.H., Baik S.H. Interleukin-15 and irisin serum concentrations are not related to cardiometabolic risk factors in patients with type 2 diabetes from Korea and Germany. Acta Diabetol. 2019:1–4. doi: 10.1007/s00592-019-01417-3.
    1. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002;8:1288–1295. doi: 10.1038/nm788.
    1. Sente T., Van Berendoncks A.M., Fransen E., Vrints C.J., Hoymans V.Y. Tumor necrosis factor-α impairs adiponectin signalling, mitochondrial biogenesis, and myogenesis in primary human myotubes cultures. Am. J. Physiol. Heart Circ. Physiol. 2016;310:H1164–H1175. doi: 10.1152/ajpheart.00831.2015.
    1. Dieli-Conwright C.M., Courneya K.S., Demark-Wahnefried W., Sami N., Lee K., Buchanan T.A., Spicer D.V., Tripathy D., Bernstein L., Mortimer J.E. Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018;36:875–883. doi: 10.1200/JCO.2017.75.7526.
    1. Abbenhardt C., McTiernan A., Alfano C.M., Wener M.H., Campbell K.L., Duggan C., Foster-Schubert K.E., Kong A., Toriola A.T., Potter J.D., et al. Effects of individual and combined dietary weight loss and exercise interventions in postmenopausal women on adiponectin and leptin levels. J. Intern. Med. 2013;274:163–175. doi: 10.1111/joim.12062.
    1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005;352:1685–1695. doi: 10.1056/NEJMra043430.
    1. Grootaert M.O., da Costa Martins P.A., Bitsch N., Pintelon I., De Meyer G.R., Martinet W., Schrijvers D.M. Defective autophagy in vascular smooth muscle cells accelerates senescence and promotes neointima formation and atherogenesis. Autophagy. 2015;11:2014–2032. doi: 10.1080/15548627.2015.1096485.
    1. Zeng G., Nystrom F.H., Ravichandran L.V., Cong L.-N., Kirby M., Mostowski H., Quon M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539–1545. doi: 10.1161/01.CIR.101.13.1539.
    1. Cusi K., Maezono K., Osman A., Pendergrass M., Patti M.E., Pratipanawatr T., DeFronzo R.A., Kahn C.R., Mandarino L.J. Insulin resistance differentially affects the PI 3-kinase–and MAP kinase–mediated signaling in human muscle. J. Clin. Investig. 2000;105:311–320. doi: 10.1172/JCI7535.
    1. Di Pino A., DeFronzo R.A. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr. Rev. 2019;40:1447–1467. doi: 10.1210/er.2018-00141.
    1. Shimobayashi M., Albert V., Woelnerhanssen B., Frei I.C., Weissenberger D., Meyer-Gerspach A.C., Clement N., Moes S., Colombi M., Meier J.A. Insulin resistance causes inflammation in adipose tissue. J. Clin. Investig. 2018;128:1538–1550. doi: 10.1172/JCI96139.
    1. Korytowski W., Wawak K., Pabisz P., Schmitt J.C., Chadwick A.C., Sahoo D., Girotti A.W. Impairment of macrophage cholesterol efflux by cholesterol hydroperoxide trafficking: Implications for atherogenesis under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2015;35:2104–2113. doi: 10.1161/ATVBAHA.115.306210.
    1. Bellanti F., Romano A.D., Buglio A.L., Castriotta V., Guglielmi G., Greco A., Serviddio G., Vendemiale G. Oxidative stress is increased in sarcopenia and associated with cardiovascular disease risk in sarcopenic obesity. Maturitas. 2018;109:6–12. doi: 10.1016/j.maturitas.2017.12.002.
    1. Gruzdeva O., Uchasova E., Dyleva Y., Akbasheva O., Matveeva V., Karetnikova V., Kokov A., Barbarash O. Relationship key factor of inflammation and the development of complications in the late period of myocardial infarction in patients with visceral obesity. BMC Cardiovasc. Disord. 2017;17:36. doi: 10.1186/s12872-017-0473-x.
    1. Atkins J.L., Whincup P.H., Morris R.W., Lennon L.T., Papacosta O., Wannamethee S.G. Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men. J. Am. Geriatr. Soc. 2014;62:253–260. doi: 10.1111/jgs.12652.
    1. Kim T.N., Choi K.M. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. J. Cell Biochem. 2015;116:1171–1178. doi: 10.1002/jcb.25077.
    1. Favre G.A., Esnault V.L., Van Obberghen E. Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. Am. J. Physiol. Endocrinol. Metab. 2015;308:E435–E449. doi: 10.1152/ajpendo.00391.2014.
    1. Jia G., Aroor A.R., Martinez-Lemus L.A., Sowers J.R. Overnutrition, mTOR signaling, and cardiovascular diseases. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014;307:R1198–R1206. doi: 10.1152/ajpregu.00262.2014.
    1. Pitt B. Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome. Hypertension. 2015;65:41–42. doi: 10.1161/HYPERTENSIONAHA.114.04117.
    1. Harper S.C., Brack A., MacDonnell S., Franti M., Olwin B.B., Bailey B.A., Rudnicki M.A., Houser S.R. Insulin Signaling and Heart Failure. Circ. Res. 2016;118:1143–1150. doi: 10.1161/CIRCRESAHA.116.307962.
    1. Yu Y., Wei S.G., Zhang Z.H., Weiss R.M., Felder R.B. ERK1/2 MAPK signaling in hypothalamic paraventricular nucleus contributes to sympathetic excitation in rats with heart failure after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2016;310:H732–H739. doi: 10.1152/ajpheart.00703.2015.
    1. Paulus W.J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013;62:263–271. doi: 10.1016/j.jacc.2013.02.092.
    1. Nishida K., Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc. Res. 2017;113:389–398. doi: 10.1093/cvr/cvx012.
    1. Kitessa S.M., Abeywardena M.Y. Lipid-induced insulin resistance in skeletal muscle: The chase for the culprit goes from total intramuscular fat to lipid intermediates, and finally to species of lipid intermediates. Nutrients. 2016;8:466. doi: 10.3390/nu8080466.
    1. Michalska-Kasiczak M., Bielecka-Dabrowa A., von Haehling S., Anker S.D., Rysz J., Banach M. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: An overview. Arch. Med. Sci. AMS. 2018;14:890. doi: 10.5114/aoms.2018.76279.
    1. Bowen T.S., Rolim N.P., Fischer T., Bækkerud F.H., Medeiros A., Werner S., Brønstad E., Rognmo O., Mangner N., Linke A. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle. Eur. J. Heart Fail. 2015;17:263–272. doi: 10.1002/ejhf.239.
    1. Suzuki T., Palus S., Springer J. Skeletal muscle wasting in chronic heart failure. ESC Heart Fail. 2018;5:1099–1107. doi: 10.1002/ehf2.12387.
    1. Banerjee D., Biggs M.L., Mercer L., Mukamal K., Kaplan R., Barzilay J., Kuller L., Kizer J.R., Djousse L., Tracy R. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ. Heart Fail. 2013;6:364–370. doi: 10.1161/CIRCHEARTFAILURE.112.000022.
    1. Sente T., Van Berendoncks A.M., Hoymans V.Y., Vrints C.J. Adiponectin resistance in skeletal muscle: Pathophysiological implications in chronic heart failure. J. Cachexia Sarcopenia Muscle. 2016;7:261–274. doi: 10.1002/jcsm.12086.
    1. Rothman D.L., Magnusson I., Cline G., Gerard D., Kahn C.R., Shulman R.G., Shulman G.I. Decreased Muscle Glucose-Transport Phosphorylation Is an Early Defect in the Pathogenesis of Non-Insulin-Dependent Diabetes-Mellitus. Proc. Natl. Acad. Sci. USA. 1995;92:983–987. doi: 10.1073/pnas.92.4.983.
    1. Ferrannini E., Simonson D.C., Katz L.D., Reichard G., Jr., Bevilacqua S., Barrett E.J., Olsson M., DeFronzo R.A. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism. 1988;37:79–85. doi: 10.1016/0026-0495(88)90033-9.
    1. DeFronzo R.A., Tripathy D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care. 2009;32:S157–S163. doi: 10.2337/dc09-S302.
    1. Cuthbertson D.J., Bell J.A., Ng S.Y., Kemp G.J., Kivimaki M., Hamer M. Dynapenic obesity and the risk of incident Type 2 diabetes: The English Longitudinal Study of Ageing. Diabet. Med. 2016;33:1052–1059. doi: 10.1111/dme.12991.
    1. Kim T.N., Park M.S., Yang S.J., Yoo H.J., Kang H.J., Song W., Seo J.A., Kim S.G., Kim N.H., Baik S.H., et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS) Diabetes Care. 2010;33:1497–1499. doi: 10.2337/dc09-2310.
    1. Grundy S.M. Metabolic syndrome update. Trends Cardiovasc. Med. 2016;26:364–373. doi: 10.1016/j.tcm.2015.10.004.
    1. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 2004;114:1752–1761. doi: 10.1172/JCI21625.
    1. Lucero D., Miksztowicz V., Macri V., López G.H., Friedman S., Berg G., Zago V., Schreier L. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α. Clín. Investig. Arterioscler. 2015;27:167–174. doi: 10.1016/j.arteri.2014.11.002.
    1. Kang S.-Y., Lim G.E., Kim Y.K., Kim H.W., Lee K., Park T.-J., Kim J. Association between sarcopenic obesity and metabolic syndrome in postmenopausal women: A cross-sectional study based on the Korean National Health and Nutritional Examination Surveys from 2008 to 2011. J. Bone Metab. 2017;24:9–14. doi: 10.11005/jbm.2017.24.1.9.
    1. Lim S., Kim J.H., Yoon J.W., Kang S.M., Choi S.H., Park Y.J., Kim K.W., Lim J.Y., Park K.S., Jang H.C. Sarcopenic obesity: Prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA) Diabetes Care. 2010;33:1652–1654. doi: 10.2337/dc10-0107.
    1. Lee J., Hong Y.-P., Shin H.J., Lee W. Associations of sarcopenia and sarcopenic obesity with metabolic syndrome considering both muscle mass and muscle strength. J. Prev. Med. Public Health. 2016;49:35. doi: 10.3961/jpmph.15.055.
    1. Scott D., Cumming R., Naganathan V., Blyth F., Le Couteur D.G., Handelsman D.J., Seibel M., Waite L.M., Hirani V. Associations of sarcopenic obesity with the metabolic syndrome and insulin resistance over five years in older men: The Concord Health and Ageing in Men Project. Exp. Gerontol. 2018;108:99–105. doi: 10.1016/j.exger.2018.04.006.
    1. Sanyal A.J., Campbell–Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., Clore J.N. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–1192. doi: 10.1053/gast.2001.23256.
    1. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 2005;115:1343–1351. doi: 10.1172/JCI23621.
    1. Kim J.K., Michael M.D., Previs S.F., Peroni O.D., Mauvais-Jarvis F., Neschen S., Kahn B.B., Kahn C.R., Shulman G.I. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Investig. 2000;105:1791–1797. doi: 10.1172/JCI8305.
    1. Kim J.K., Zisman A., Fillmore J.J., Peroni O.D., Kotani K., Perret P., Zong H., Dong J., Kahn C.R., Kahn B.B. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J. Clin. Investig. 2001;108:153–160. doi: 10.1172/JCI10294.
    1. Wijarnpreecha K., Panjawatanan P., Aby E., Ahmed A., Kim D. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity. Maturitas. 2019;124:48–54. doi: 10.1016/j.maturitas.2019.03.016.
    1. Buechler C., Haberl E.M., Rein-Fischboeck L., Aslanidis C. Adipokines in liver cirrhosis. Int. J. Mol. Sci. 2017;18:1392. doi: 10.3390/ijms18071392.
    1. Budick-Harmelin N., Dudas J., Demuth J., Madar Z., Ramadori G., Tirosh O. Triglycerides potentiate the inflammatory response in rat Kupffer cells. Antioxid. Redox Signal. 2008;10:2009–2022. doi: 10.1089/ars.2007.1876.
    1. Jiang W., Wu N., Wang X., Chi Y., Zhang Y., Qiu X., Hu Y., Li J., Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci. Rep. 2015;5:8096. doi: 10.1038/srep08096.
    1. Kim G., Lee S.E., Lee Y.B., Jun J.E., Ahn J., Bae J.C., Jin S.M., Hur K.Y., Jee J.H., Lee M.K. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study. Hepatology. 2018;68:1755–1768. doi: 10.1002/hep.30049.
    1. Tovo C.V., Fernandes S.A., Buss C., de Mattos A.A. Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review. World J. Hepatol. 2017;9:326. doi: 10.4254/wjh.v9.i6.326.
    1. Hong H.C., Hwang S.Y., Choi H.Y., Yoo H.J., Seo J.A., Kim S.G., Kim N.H., Baik S.H., Choi D.S., Choi K.M. Relationship Between Sarcopenia and Nonalcoholic Fatty Liver Disease: The Korean Sarcopenic Obesity Study. Hepatology. 2014;59:1772–1778. doi: 10.1002/hep.26716.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe